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Available online 20 April 2016Background: Fatty liver (hepatic steatosis) is one of the most common diseases globally, with increasing preva-
lence. The role of alcohol consumption in the development of hepatic steatosis has not been systematically exam-
ined.
Methods:We searchedMedline, Embase, and ProQuest Dissertations & Theses Global for original data on the re-
lationship between alcohol consumption and hepatic steatosis measured by non-invasive imagery, excluding
studies conducted in participants b18 years, or subgroups related to viral and drug-induced liver disease. We
identiﬁed 18 articles reporting adjusted data (Japan=11, other high-income countries=7). Random-effect cat-
egorical meta-analyses (b20 g/day pure alcohol consumption vs non-drinkers) and dose-response meta-
analyses for the whole range of alcohol consumption were conducted.
Results: In total, 99,370 participants and 25,662 cases of hepatic steatosis were included. In Japan, low alcohol
consumption was consistently associated with substantially reduced incidence and prevalence of hepatic
steatosis compared tonon-drinkers (RR for b20 g pure alcohol/day=0.75, 95% CI: 0.71–0.79, I2=0%). No overall
association was found in other countries (RR = 1.05, 95% CI: 0.86–1.30, I2 = 84%). Dose-response analyses in
Japan (up to 80 g/day) showed an inverse relationship in men and a J-shape in women.
Conclusions: Alcohol consumption showed a complex association with hepatic steatosis with substantial differ-
ences by ethnicity and sex. Low alcohol consumption was beneﬁcial in Japan with good epidemiological evi-
dence, whereas there was no association in other countries. However, heterogeneity was large in countries
other than Japan. More and higher quality research in diverse ethnic populations is needed to further clarify
this relationship.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Liver diseases are prevalent diseases in all regions of the world
(Lozano et al., 2012), and associated with marked burden of disease
(Byass, 2014). Aside from viral hepatitis, the leading cause for livernd Mental Health, Social and
et, Toronto, Ontario M5S 2S1,
. This is an open access article underdisease globally, for all stages of liver disease from hepatic steatosis to
liver cirrhosis, there is a basic distinction into alcoholic versus non-
alcoholic forms based on the history of alcohol intake with various
cut-points (mostly between 20 and 40 g pure alcohol intake per day
[g/day]) (Chalasani et al., 2012; LaBrecque et al., 2014; EASL, 2012;
Nascimbeni et al., 2013).
The prevalence of non-alcoholic fatty liver disease (NAFLD), now
more common than alcoholic liver disease (Sattar et al., 2014), has dou-
bled in both North America and Asia over the past two decades, and it
has become one of the most widespread chronic conditions worldwidethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Targher, 2015; Vernon et al., 2011; Younossi et al., 2015). It is frequently
associated with impaired glucose tolerance, insulin resistance, hyper-
tension, and obesity (Yki-Jarvinen, 2014), and a risk factor for both
type 2 diabetes mellitus and the metabolic syndrome (MetS) (Ballestri
et al., 2015), all of which are risk factors for cardiovascular diseases
and overall mortality. Hepatic steatosis might also be an independent
risk factor for cardiovascular disease (Bonci et al., 2015; Lu et al.,
2013; Targher et al., 2010; Loria et al., 2014). Aside from other causes
of liver disease (such as use of medication or presence of hereditary dis-
orders known to produce hepatic lipidosis, or viral hepatitis B or C),
non-alcoholic hepatic steatosis is diagnosed based on hepatic fatty inﬁl-
tration in the absence of excessive alcohol consumption (Neuman et al.,
2014a). However, there are no systematic investigations as to what ex-
cessive alcohol consumption means for hepatic steatosis (Nascimbeni
et al., 2013), or whether the relationship between alcohol consumption
and hepatic steatosis is continuous or characterized by a threshold ef-
fect. Furthermore, the role of sex in this relationship is not clear
(Vernon et al., 2011).
Several conﬂicting large-scale population-based studies published
recently (e.g. (Lau et al., 2015; Moriya et al., 2015; Tsunoda et al.,
2014)) indicated that moderate (or ‘non-alcoholic’) alcohol consump-
tion either has a beneﬁcial or detrimental association with prevalence
or development of hepatic steatosis, questioning the distinction into
non-alcoholic and alcoholic hepatic steatosis. Furthermore, the impact
of irregular heavy (binge) drinking on liver disease among moderate
drinkers is currently unknown (Mathurin and Deltenre, 2009; Rehm
and Roerecke, 2015). In the US, an episodic heavy drinking pattern is
more common than chronic heavy drinking (Naimi et al., 2003;
MMWR Morbidity and Mortality Weekly Report 2012, 2010), and the
prevalence of heavy episodic drinking is high or on the rise in many
countries (Shield et al., 2013).
The objective of this study was to determine the relationship be-
tween patterns of alcohol consumption and hepatic steatosis, taking
into account confounding from other risk factors for hepatic steatosis.
We systematically examined the epidemiological evidence for the rela-
tionship between patterns of alcohol consumption (including totalFig. 1. Flowchart ofaverage amount and ‘binge’ drinking) and prevalence and incidence of
non-alcoholic hepatic steatosis, stratiﬁed by sex where possible. Non-
linear dose-response analyseswere conductedwithout a distinction be-
tween alcoholic and non-alcoholic hepatic steatosis.
2. Material and Methods
2.1. Search Strategy and Selection Criteria
Following the Guidelines for Meta-Analyses and Systematic Reviews
of Observational Studies (MOOSE) (Stroup et al., 2000), we conducted a
systematic literature search (Fig. 1, Table S1) using Medline, Embase,
and ProQuest Dissertations & Theses Global, updated on December 10,
2015 for keywords relating to alcohol consumption and fatty liver dis-
ease. Additionally, we searched reference lists of identiﬁed articles and
published meta-analyses and reviews. Inclusion criteria were: 1) full-
text article with original and adjusted population-based data (cross-
sectional or cohort design) on the relationship between alcohol con-
sumptionandhepatic steatosis in comparison tonon-drinkers, 2)hepat-
ic steatosis was diagnosed using non-invasive methods (ultrasound,
computed-tomography, magnetic resonance imaging, proton magnetic
resonance spectroscopy), 3) results were reported in categories of alco-
hol consumption in relation to non-drinkers. For categorical meta-
analyses, at least one category had to report results for alcohol con-
sumption between 0 and 20 g/day (0–40 g/day in a sensitivity analysis)
in comparison to non-drinkers. For a dose-response meta-analysis, re-
sults for at least three drinking groups based on average intake in g/
day in comparison to non-drinkers had to be reported. We excluded
studies with participants or ultrasound examinations were restricted
to or based on: a) b18 years of age, b) viral hepatitis (HBV or HCV),
c) drug-induced liver disease, or d) other indications of liver disease
(e.g. elevated liver function tests (Bellentani et al., 1997)),
e) experimental conditions. No language restrictions were applied.
Two reviewers independently excluded articles based on title and ab-
stract on the ﬁrst pass, articles with unsure eligibility were obtained in
full-text and discussed by two authors until consensuswas reached. Au-
thors were not contacted.study selection.
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From all relevant articles we extracted authors' names, year of pub-
lication, country, calendar year(s) of baseline examination, follow-up
period, setting of the study, assessment of hepatic steatosis status, age
(meanormedian) at baseline, sex, number of observed hepatic steatosis
cases among participants by drinking group, number of total partici-
pants by drinking group, speciﬁc adjustment or stratiﬁcation for poten-
tial confounders, and adjusted relative risks (RRs) and their conﬁdence
intervals (CIs) or standard errors. Estimates by sex and study design
were treated as independent samples. As a result, multiple articles and
estimates from the same samples and cohorts in Japan (Moriya et al.,
2015; Moriya et al., 2013; Moriya et al., 2011; Hamaguchi et al., 2012;
Hamaguchi et al., 2005; Hashimoto et al., 2015) were included, but
each case of hepatic steatosis was used only once in each of the analyses
conducted. If necessary, RRs within studies were re-calculated based on
themethod described byHamling and colleagues (Hamling et al., 2008)
to contrast several alcohol consumption categories against non-
drinkers.
2.3. Outcome Assessment
Histopathology (liver biopsy) is considered the gold standard for di-
agnosis of NAFLD since it is a direct visualization of the liver, can quan-
tify the amount of lipids and can assess the presence of inﬂammation
and ﬁbrosis. However, liver biopsy is an invasive procedure associated
with sampling error and may lead to complications. Because we were
interested in population-based risk relationships, hepatic steatosis in
our analysis had to be measured by non-invasive imagery. Ultrasound
and comparable imaging techniques have very good speciﬁcity (94%)
and sensitivity (85%) in people who are not morbidly obese (Hernaez
et al., 2011).
2.4. Exposure Assessment
Among drinkers, we converted reported average total alcohol intake
categories in primary studies into g/day using the midpoints (mean) of
reported drinking group categories. For open-ended categories, we
added ¾ of the second highest category's range to the lower limit of
the open-ended category of drinking.We used reported conversion fac-
tors when standard drinks were the unit of measurement. Depending
on the country, one standard drink is approximately 10–14 g of pure al-
cohol (WHO, 2000). Qualitative descriptions, such as ‘social’ or ‘fre-
quent’ drinkers with no clear total alcohol intake were excluded.
2.5. Quality Assessment
Most quality scores are tailored formeta-analyses of randomized tri-
als of interventions (Chalmers et al., 1981; Detsky et al., 1992; Moher
et al., 1998) and many criteria do not apply to epidemiological studies
examined in this study. Additionally, quality score use in meta-
analyses remains controversial (Greenland and O'Rourke, 2001;
Herbison et al., 2006). As a result, quality assessment was incorporated
by including quality components, such as study design,measurement of
alcohol consumption and hepatic steatosis, in the inclusion and exclu-
sion criteria, and further by investigating potential heterogeneity in
meta-regression models and several subgroup analyses. We used the
most adjusted RR reported and the most comprehensive data available
for each analysis, and gave priority to estimates where lifetime ab-
stainers were used as the risk reference group.
2.6. Categorical Analyses
The prevalence (proportion) of hepatic steatosis by drinking group
(non-drinkers and drinkers b20 g/day) across studies included in the
meta-analysis was calculated from the raw number of cases and non-cases reported and pooled in randomeffectsmodelswith conﬁdence in-
tervals calculated based on the exact binomial distribution (Newcombe,
1998) and variances stabilized with the Freeman and Tuckey double-
arcsine transformation (Freeman and Tukey, 1950).
We conducted categorical meta-analyses (main analysis on alcohol
consumption b20 g/day in comparison to non-drinkers) using reported
adjusted data stratiﬁed by: 1) country of study origin (Japan vs other
countries), 2) sex (men vs women), and 3) study design (prevalence
vs incidence data). Because a clear deﬁnition of excessive alcohol con-
sumption for hepatic steatosis ismissing (Chalasani et al., 2012), though
it ranges between 20 and 40 g/day (Nascimbeni et al., 2013; Poli et al.,
2013), as a sensitivity analysis, we repeated the main categorical
meta-analysis with a cut-point of 40 g/day. RRs were pooled with
inverse-variance weighting using DerSimonian-Laird random-effect
models to allow for between-study heterogeneity (DerSimonian and
Laird, 1986). Publication bias was examined using Egger's regression-
based test (Egger et al., 1997). Variation in the effect size because of het-
erogeneity between-studies was quantiﬁed using the I2 statistic
(Higgins and Thompson, 2002). Between-study heterogeneity across
subgroups deﬁned by sex, study design, and country of study origin
was investigated with random-effects meta-regressions (Thompson
and Higgins, 2002). All meta-analytical analyses were conducted on
the natural log scale in Stata statistical software, version 13.1.
2.7. Dose-response Analyses
Ignoring a distinction between ‘alcoholic’ and ‘non-alcoholic’ hepatic
steatosis, we conducted two-stage multivariate meta-regression using
restricted cubic spline regressionmodels (3 knots) to calculate continu-
ous non-linear dose-response curves for average alcohol consumption
(g/day) in comparison to non-drinkers using the approach described
by Orsini and colleagues (Orsini et al., 2006; Orsini et al., 2012). Only ad-
justed data with ≥3 drinking groups in addition to non-drinkers were
used in these analyses. Evidence for non-linearity was determined by
the signiﬁcance level of the second meta-regression coefﬁcient. Sex-
and design-speciﬁc dose-response analyses were conducted where
such data were available.
Role of Funding Source
The work was ﬁnancially supported by a grant from the National In-
stitute on Alcohol Abuse and Alcoholism (NIAAA) at the National Insti-
tutes of Health (grant number R21AA023521-01A1 toMR). The sponsor
of the study had no role in study design, data collection, data analysis,
data interpretation, or writing of the report. The authors collected the
data, and had full access to all of the data in the study. The authors
also had ﬁnal responsibility for the decision to submit the study results
for publication.
3. Results
Of 1527 initial references, 245 were reviewed in full-text (Fig. 1). In
total we used data from 18 articles including 25,662 cases of hepatic
steatosis among 99,370 participants in the analyses, with sex-speciﬁc
data from 12,203 men and 4731 women with hepatic steatosis
(Table 1). Eleven articles (n = 72.394) were from Japan (Moriya et al.,
2015; Tsunoda et al., 2014; Moriya et al., 2013; Moriya et al., 2011;
Hamaguchi et al., 2012; Hamaguchi et al., 2005; Hashimoto et al.,
2015; Gunji et al., 2009; Hiramine et al., 2011; Doi et al., 2010;
Hamabe et al., 2011) and seven (n = 26.976) from other high-income
countries (US (Lazo, 2010), Germany (Lau et al., 2015), Finland
(Suomela et al., 2015), Italy (Miele et al., 2014), Spain (Caballeria
et al., 2010), and China (Peng et al., 2009; Xu et al., 2010; Wong et al.,
2012; Liu et al., 2014)). Weighted mean age at baseline was 47.2 years
overall (Japan 48.1, other countries 44.9 years) with a range from 42
to 53 years. Five studies from Japan (Moriya et al., 2015; Tsunoda
Table 1
Study characteristics of 18 adjusted population-based studies on alcohol consumption and hepatic steatosis compared to non-drinkers.
Reference Sex,
Country,
Year(s) of
baseline
Setting, Age Design, No. Participants excluded Alcohol
consumption
measurement
Hepatic steatosis
measurement
Adjustment
Hamaguchi
et al.
(2005)
M, W,
Japan,
2001–2003
Murakami Memorial
Hospital, Health
screening, 48 yrs
Cohort, 1093
cases, 3589
non-cases
Positive for hepatitis B
antigen or hepatitis C
antibody, history of known
liver disease or current
medication, viral, genetic,
autoimmune, and
drug-induced liver disease
Non-drinker,
b20 g/day
Excluded: N20
g/day
Ultrasound
The diagnosis of fatty liver
was based on the results of
abdominal ultrasonography
by trained technicians. All
ultrasonographic images
were stored in the image
server. One
gastroenterologist reviewed
the images and made the
diagnosis of fatty liver
without reference to any of
the participant's other
individual data. Of four
known criteria (hepatorenal
echo contrast, liver
brightness, deep
attenuation, and vascular
blurring), the participants
were required to have
hepatorenal contrast and
liver brightness to be given
a diagnosis of nonalcoholic
fatty liver disease.
Age, MetS, weight gain
Gunji et al.
(2009)
M, Japan,
2007–2008
Center for Preventive
Medicine, NTT Kanto
Medical Center, Health
screening, 50.9 yrs
Cross-sectional,
1865 cases,
3702 non-cases
Positive for HBV or HCV,
potentially hepatotoxic
drug intake, medical
treatment for metabolic
abnormalities
(hypertension,
hyperlipidemia, or diabetes
mellitus).
Non or
minimal
drinkers (b40
g/week),
40–140
g/week
Excluded:
N140 g/week
Ultrasound
Details not reported.
Age, BMI, waist
circumference, visceral
adipose tissue,
subcutaneous adipose
tissue, systolic blood
pressure, diastolic blood
pressure, high-density
lipoprotein cholesterol,
low-density lipoprotein
cholesterol, triglyceride,
fasting blood glucose,
glycated hemoglobin
Xu et al.
(2010)
M/W,
China,
2006–2009
Employees of Zhenhai
Reﬁning & Chemical
Company, Health
screening, 44 yrs
Cohort, 813
cases, 6077
non-cases
Fatty liver at baseline,
lipid-lowering agents, or
hypouricemic agents based
on self-reported medical
history and medication use,
a positive history of known
liver disease (such as HBV
or HCV) or autoimmune
hepatitis, or use of
hepatotoxic medications
(including hypertensive or
antidiabetic agents).
Non-drinkers,
b140 g/week
men, b70
g/week
women
Excluded:
N140 g/week
men, N70
g/week
women
Ultrasound
Abdominal ultrasonography
using a Toshiba Nemio 20
sonography machine with a
3.5-MHz probe (Toshiba,
Tokyo, Japan). Ultrasound
studies were carried out by
a trained ultrasonographist
who was unaware of the
clinical and laboratory data.
Hepatic steatosis was diag-
nosed by characteristic echo
patterns according to con-
ventional criteria, such as
the evidence of diffuse
hyperechogenicity of the
liver relative to the kidneys,
ultrasound beam
attenuation, and poor visu-
alization of intrahepatic
structures.
Age, gender, BMI, waist
circumference, systolic
blood pressure, diastolic
blood pressure, alanine
aminotransferase, aspartate
aminotransferase,
γ-glutamyl transpeptidase,
total cholesterol,
high-density lipoprotein
cholesterol, low-density
lipoprotein cholesterol,
triglyceride, fasting plasma
glucose, creatinine, blood
urea nitrogen, serum uric
acid
Caballeria
et al.
(2010)
M/W,
Spain,
2007–2008
Multicentre (25
primary health care
centres),
Population-based, 53
yrs
Cross-sectional,
198 cases, 568
non-cases
Chronic liver disease,
hepatitis B virus surface
antigen or hepatitis C virus
antibodies, incapacitating
diseases, cognitive
deterioration,
institutionalized patients,
no ﬁxed address
Never
drinkers, ≤30
g/day men,
≤20 g/day
women
Excluded: N30
g/day men,
N20 g/day
women
Ultrasound
The criteria for the
diagnosis of NAFLD
included an increase in
hepatic echogenicity using
renal echogenicity as a
reference, the presence of
enhancement and a lack of
differentiation of periportal
and bile duct walls
reinforcement because of
great hyperechogenicity of
the parenchyma. The grade
of involvement was
standardized using a
Age, sex, radiologist
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Table 1 (continued)
Reference Sex,
Country,
Year(s) of
baseline
Setting, Age Design, No. Participants excluded Alcohol
consumption
measurement
Hepatic steatosis
measurement
Adjustment
semiquantitative scale of
the grade of hepatic
enhancement.
Doi et al.
(2010)
M/W,
Japan,
2008
Health examinations,
Oji General Hospital,
Health screening, 51
yrs
Cross-sectional,
1032 cases,
2153 non-cases
HBsAg positive, HCV
antibody-positive,
autoimmune chronic liver
disease, incomplete
description of alcohol
consumption
Non-drinkers,
b20 g/d, 20- b
40 g/d, 40- b
60 g/d, ≥60
g/d
Excluded:
none
Ultrasound
Details not reported.
Age, sex, visceral fat obesity,
dyslipidemia, high fasting
glucose
Lazo
(2010)
M/W,
United
States,
1988–1994
Part of NHANES III
(nationwide),
Population-based, 43
yrs
Cross-sectional,
2515 cases,
9599 non-cases
None Never
drinkers, b2
drink/d men,
b1 drink/d
women, ≥2
drinks/d men,
≥1 drink/d
women
Excluded:
none
Ultrasound
Moderate or severe
steatosis. Ultrasound
examinations on the
gallbladder were carried out
using a Toshiba (Tustin, CA)
SSA-90 A machine using
3.75 and 5.0 MHz
transducer. Between 2009
and 2010, 13,856 (96.6%) of
the archived videotapes on
gallbladder ultrasound
examinations originally
obtained between 1988 and
1994 were reviewed to
ascertain the presence of fat
within the hepatic
parenchyma. Information
was recorded on the
presence of liver to kidney
contrast, degree of
brightness of the liver
parenchyma, presence of
deep beam attenuation,
presence of echogenic walls
in the small intrahepatic
vessels, and deﬁnition of the
gallbladder walls.
Age, sex, race, BMI, diabetes
Hamabe
et al.
(2011)
M/W,
Japan,
1998–2008
Kouseiren Medical
Health Care Center,
Kagoshima, Health
screening, 50 yrs
Cohort, 735
cases, 2854
non-cases
Subjects positive for
hepatitis B virus surface
antigen (HBsAg) and
hepatitis C virus antibody
(HCV Ab) and those who
did not undergo virus
marker measurements
Non-drinker,
≤20 g/day
Excluded: N20
g/day
Ultrasound
Fatty liver was diagnosed
when hepato-renal echo
contrast and liver
brightness were observed.
The diagnosis of fatty liver
was subsequently
conﬁrmed by a specialist
physician independently
without reference to other
data.
Age, sex, obesity,
hypertension, dyslipidemia,
dysglycemia, smoking
Hiramine
et al.
(2011)
M, Japan,
2000–2007
Kouseiren Medical
Health Care Center,
Kagoshima, Health
screening, 51 yrs
Cross-sectional,
3816 cases,
6070 non-cases
Positive for HBV surface
antigen, HCV antibody
Never
drinkers,
former
drinkers, b20
g/d, 20–59
g/d, ≥60 g/d
Excluded:
none
Ultrasound
Ultrasonography (SSA-250A
and SSA-700A; Toshiba,
Tokyo, Japan; Logic 400; GE
Healthcare Japan, Tokyo,
Japan), from ﬁndings of
bright liver (increased
echogenicity) with liver–-
kidney contrast (increased
echogenicity of the liver in
comparison to the right
kidney).
Age, BMI, presence of
clinical manifestation (ALT
elevation, hypertension,
dyslipidemia, diabetes
mellitus), smoking status,
serum levels of alanine
aminotransferase,
γ-glutamyl transpeptidase,
triglycerides, and
high-density lipoprotein
cholesterol
Moriya
et al.
(2011)
M, Japan,
2003
Junpukai Health
Maintenance Center,
Health screening, 49
yrs
Cross-sectional,
1563 cases,
3394 non-cases
Past or presently treated
liver diseases
Non-drinkers,
b70 g/week,
70– b 140
g/week, 140–
b 280 g/week,
≥280 g/week;
Stratiﬁed by
drinking days
per week and
amount per
Ultrasound
Experienced technicians
performed real-time
ultrasonography to detect
vascular blurring, deep
attenuation and increased
liver echotexture in
comparison to the kidneys
(liver-kidney contrast) to
assess fatty inﬁltration.
Specialists subsequently
Obesity (BMI ≥ 25),
atherogenic dyslipidemia,
glucose intolerance,
hyperuricemia,
hypertension and regular
exercise
(continued on next page)
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Table 1 (continued)
Reference Sex,
Country,
Year(s) of
baseline
Setting, Age Design, No. Participants excluded Alcohol
consumption
measurement
Hepatic steatosis
measurement
Adjustment
drinking day
Excluded:
none
conﬁrmed the validity of
the ﬁndings and judged the
presence of one or more
ﬁndings as indicative of a
fatty liver.
Wong
et al.
(2012)
M/W,
China,
2008–2010
Randomly selected
from the census
database at Prince of
Wales Hospital,
Population-based, 48
yrs
Cross-sectional,
264 cases, 658
non-cases
Active malignancy, metallic
implants or other
contraindications to MRI,
positive hepatitis B surface
antigen or antibody against
hepatitis C virus, secondary
causes of fatty liver
(e.g., consumption of amio-
darone and tamoxifen) and
decompensated liver dis-
ease (deﬁned as bilirubin
N50 mmol/l, albumin b35
g/l, platelet count
b1.503,109/l, international
normalised ratio N 1.3, or
the presence of ascites or
varices)
Non-drinkers,
≤10 g/d
Excluded: N10
g/d
Proton-magnetic resonance
spectroscopy
H-MRS was performed to
measure intrahepatic
triglyceride (IHTG) content
within 8 weeks from the
baseline visit. A whole-body
3.0 T scanner with a single
voxel point-resolved
spectroscopy sequence and
an echo time of 40 ms and
repetition time of 5000 ms
was used. A survey scan was
ﬁrst performed in the
abdominal region to help in
positioning a volume
measuring 20 (AP) 315 (RL)
340 (FH) mm within the
liver. The scanner's built-in
body coil was used for both
signal transmission and
reception. A
no-water-suppressed
spectrum was acquired
using 32 signal averages
and the data were exported
for ofﬂine spectral analysis.
Water (4.65 ppm) and lipid
(1.3 ppm) peak amplitudes
were measured to
determine vertebral
marrow fat content, which
was deﬁned as the relative
fat signal amplitude in
terms of a percentage of the
total signal amplitude
(water and fat). Correction
for relaxation loss was not
applied because of the
relatively long repetition
time and short echo time.
An IHTG content of 5% was
used to distinguish between
patients with and without
fatty liver.
Age, gender, MetS
Hamaguchi
et al.
(2012)
M, W,
Japan,
2004–2009
Murakami Memorial
Hospital, Health
screening, 47 yrs
Cross-sectional,
6282 cases,
12,290
non-cases
Positive for hepatitis B
antigen or hepatitis C
antibody, history of known
liver disease or current
medication, viral, genetic,
autoimmune, and
drug-induced liver disease.
Non- or
minimal
drinkers (b40
g/week),
40–140
g/week
,140–280
g/week, N280
g/week
Excluded:
none
Ultrasound
The diagnosis of fatty liver
was based on the results of
abdominal ultrasonography
by trained technicians. All
ultrasonographic images
were stored in the image
server. One
gastroenterologist reviewed
the images and made the
diagnosis of fatty liver
without reference to any of
the participant's other
individual data. Of 4 known
criteria (hepato-renal echo
contrast, liver brightness,
deep attenuation, and
vascular blurring), the
participants were required
to have hepato-renal
contrast and liver
brightness to be given a
diagnosis of non-alcoholic
Age, medication potentially
affecting MetS, regular
exercise, smoking status
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Table 1 (continued)
Reference Sex,
Country,
Year(s) of
baseline
Setting, Age Design, No. Participants excluded Alcohol
consumption
measurement
Hepatic steatosis
measurement
Adjustment
fatty liver disease.
Moriya
et al.
(2013)
W, Japan,
2003–2006
Junpukai Health
Maintenance Center,
Health screening, 46
yrs
Cross-sectional,
527 cases, 2876
non-cases
Concurrent liver diseases Non-drinkers,
b70 g/week,
70- b 140
g/week, ≥140
g/week
Excluded:
none
Ultrasound
Experienced technicians
performed real-time
ultrasonography to detect
vascular blurring, deep
attenuation and increased
liver echotexture in
comparison to the kidneys
(liver-kidney contrast) to
assess fatty inﬁltration.
Specialists subsequently
conﬁrmed the validity of
the ﬁndings and judged the
presence of one or more
ﬁndings as indicative of a
fatty liver.
Age, obesity, atherogenic
dyslipidemia, glucose
intolerance, hyperuricemia,
hypertension, current
smoking
Liu et al.
(2014)
W, China,
2012
Department of
Medical Examination
Center, Peking Union
Medical College
Hospital, China Aca-
demic Medical
Science, Health
screening, 53 yrs
Cross-sectional,
121 cases, 407
non-cases
Non-obese (BMI b 25) and
postmenopausal women
were included. SUA levels
that were out of the normal
reference range, hormone
replacement therapy or
medication potentially
affecting SUA levels, serum
creatinine level ≥ 1.2 mg/dl,
previous use of steatogenic
medications, any evidence
of chronic viral liver disease
and/or autoimmune liver
disease, evidence of liver
insufﬁciency or malignancy.
Non-drinkers,
b10 g/d
Excluded: ≥10
g/day
Ultrasound
NAFLD was deﬁned as the
presence of deﬁnite hepatic
steatosis on
ultrasonography, such as a
bright hepatic echo pattern,
increased attenuation of the
echo beam and loss of
intrahepatic architectural
detail, without a secondary
cause. Ultrasonography of
the liver was performed
using a 3.5-MHz
convex-array probe and a
7.5-MHz linear-array probe
(Nemio 30, Toshiba, Japan)
by an experienced examiner
who was unaware of the
laboratory and other results.
Age, waist circumference,
SBP, DBP, GGT, ALT, AST,
blood urea nitrogen,
creatinine, fasting blood
glucose, TC, TG, HDL\\C,
LDL-C, serum uric acid,
C-reactive protein, diabetes,
hypertension, MetS,
smoking status
Tsunoda
et al.
(2014)
M/W,
Japan,
2005–2013
Meiji Yasuda Shinjuku
Medical Center (Meiji
Yasuda Longitudinal
Study), Health
screening, 48 yrs
Cohort, 1775
cases, 8371
non-cases
Histories of liver disease
(HBV or HCV, cirrhosis and
hepatic hemangioma, drugs
associated with hepatic
disease or antibodies to HBV
or HCV), fatty liver at
baseline, could not be
followed up for ≥1 yr
Non-drinkers,
b23 g/day
Excluded: ≥23
g/day
Ultrasound
Abdominal ultrasonography
machines (EUB-2000,
Hitachi, Japan; and SSA-340,
550, 580 and 660, Toshiba,
Japan) were used to diag-
nose fatty liver based on
standard criteria, including
hepato-renal echo contrast,
liver brightness, deep atten-
uation and vascular blur-
ring. To enhance diagnostic
accuracy, the ultrasound
images were evaluated in
three steps: ﬁrst, a trained
medical technologist per-
formed the ultrasound and
provided opinions with im-
ages to the doctor; second,
the doctor made a diagnosis
based on this information
and third, a group of medi-
cal technologists including
the original examiner con-
ﬁrmed the doctor's
diagnosis.
Age, gender, BMI, smoking
status, family history of liver
disease, alanine
aminotransferase,
γ-glutamyl transpeptidase,
hypertension, diabetes,
dyslipidemia, meat intake,
vegetable intake, physical
activity
Lau et al.
(2015)
M, W,
Germany,
1997–2001
Study of Health in
Pomerania (SHIP),
Population-based, 50
yrs
Cross-sectional,
1120 cases,
2638 non-cases
Positive for HBV surface
antigen or HCV antibody,
known history of liver
cirrhosis
Men:
non-drinkers,
b40 g/d,
40–60 g/d,
N60 g/d;
Women:
non-drinkers,
b20 g/d,
20–40 g/d,
N40 g/d;
Ultrasound
Sonographic examinations
were performed by
physicians using a 5 MHz
transducer and a high
resolution instrument
(Vingmed VST Gateway,
Santa Clara, CA, USA). The
sonographers were
unaware of the participants'
Age, BMI, HbA1c,
menopausal status
(continued on next page)
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Table 1 (continued)
Reference Sex,
Country,
Year(s) of
baseline
Setting, Age Design, No. Participants excluded Alcohol
consumption
measurement
Hepatic steatosis
measurement
Adjustment
Binge
drinking (≥5
drinks/day at
least once
during the
last 30 days)
among
drinkers.
Excluded:
none
clinical and laboratory
characteristics. Hepatic
steatosis was deﬁned as the
presence of a
hyperechogenic liver
pattern, with evident
density differences between
hepatic and renal
parenchyma.
Moriya
et al.
(2015)
M/W,
Japan,
2003–2006
Junpukai Health
Maintenance Center,
Health screening, 48
yrs
Cohort, 449
cases, 3434
non-cases
Presently treated liver
diseases
Non-drinkers,
b70 g/week,
70.0– b 140
g/week,
140.0– b 280
g/week, ≥280
g/week
Excluded:
none
Ultrasound
Experienced technicians
performed real-time
ultrasonography to detect
vascular blurring, deep
attenuation and increased
liver echotexture in
comparison to the kidneys
(liver-kidney contrast) to
assess fatty inﬁltration.
Specialists subsequently
conﬁrmed the validity of
the ﬁndings and judged the
presence of one or more
ﬁndings as indicative of a
fatty liver.
Obesity, smoking status,
and regular exercise
Suomela
et al.,
(2015)
M/W,
Finland,
2011
Cardiovascular Risk in
Young Finns Study,
Population-based, 42
yrs
Cross-sectional,
370 cases, 1628
non-cases
None Non-drinkers,
b1.67
drinks/d
Excluded:
≥1.67
drinks/d
Ultrasound
Ultrasound imaging of the
liver was performed using a
validated protocol (Loria
et al., 2014) and Sequoia
512 ultrasound mainframes
(Acuson, Mountain View,
CA, USA) with 4.0 MHz
adult abdominal
transducers. Evaluation of
hepatic steatosis was
performed according to
liver-to-kidney contrast,
parenchymal brightness,
deep beam attenuation, and
bright vessel walls.
According to these criteria
the presence of hepatic
steatosis was assessed
visually from non-blinded
images by a trained
ultrasonographer.
Age, sex
Stratiﬁed by BMI (b25 and
≥25).
Hashimoto
et al.
(2015)
M, W,
Japan,
1994–2003
Murakami Memorial
Hospital, Health
screening, 43 yrs
Cohort, 1124
cases, 3400
non-cases
Positive for hepatitis B
antigen or hepatitis C
antibody, history of known
liver disease, any current
medication, viral, genetic,
autoimmune, and
drug-induced liver disease
None or
minimal (b40
g/week),
40–140
g/week,
140–280
g/week, N280
g/week
Excluded:
none
Ultrasound
Abdominal
ultrasonography, which was
done by trained technicians
with Aloka SSD-650CL
(Aloka Co., Ltd, Tokyo,
Japan). Gastroenterologists
reviewed the images and
made the diagnosis of fatty
liver without reference to
any of the participant's oth-
er individual data. Of four
known criteria (hepatorenal
echo contrast, liver
brightness, deep
attenuation, and vascular
blurring), the participants
were required to have
hepatorenal contrast and
liver brightness to be given
a diagnosis of fatty liver.
Age, BMI, physical activity,
smoking status
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, bodymass index; DBP, diastolic blood pressure; GGT,γ-glutamyl transferase; HBV, hepatitis B; HCV, hepatitis
C; HDL-C, high-density cholesterol; LDL-C, low-density cholesterol;MetS,metabolic syndrome; SBP, systolic blood pressure; SUA, serumuric acid; TC, total cholesterol; TG, triglyceride;M,
men; W, women; M/W, men and women combined; M,W, men and women stratiﬁed.
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325M. Roerecke et al. / EBioMedicine 8 (2016) 317–330et al., 2014; Hamaguchi et al., 2005; Hashimoto et al., 2015; Hamabe
et al., 2011), and one study from China (Xu et al., 2010) provided inci-
dence data. The weighted mean follow-up time in cohort studies was
7 years (range 1 to 10 years). All but one (Moriya et al., 2015) studies
were adjusted for age, and all but three (Hamaguchi et al., 2012;
Caballeria et al., 2010; Wong et al., 2012) for BMI, visceral fat, or waist
circumference. All but ﬁve studies (Lau et al., 2015; Moriya et al.,
2015; Hashimoto et al., 2015; Suomela et al., 2015; Caballeria et al.,
2010) adjusted for multiple components of the MetS.
3.1. Categorical Meta-analyses
Table 2 displays pooled adjusted RRs by country, sex, and study de-
sign for the relationship between alcohol consumption b20 g/day and
hepatic steatosis in comparison to non-drinkers. In studies from Japan,
the relationship was beneﬁcial in all analyses (adjusted prevalence
and incidence data RR = 0.75, 95% CI: 0.71–0.79, P b 0.001, Fig. 2,
Table 2). Studies from other high-income countries showed no overall
association (adjusted prevalence and incidence data RR = 1.05, 95%
CI: 0.86–1.30, P = 0.62, Fig. 2, Table 2). Whether or not studies were
from Japan explained 64% of the overall between-study variation
(RR = 0.71, 95% CI: 0.59–0.85, P = 0.001). There was virtually no
change when alcohol consumption b40 g/day in comparison to non-
drinkers was considered in a sensitivity analysis (0.73, 95% CI: 0.68–
0.78, and 1.07, 95% CI: 0.86–1.34, respectively). One study from Japan
(Hiramine et al., 2011) and two from other countries (Lazo, 2010;
Caballeria et al., 2010) had data on lifetime abstainers and showed the
same differences in RRs (adjusted RR = 0.71, 95% CI: 0.59–0.86 in
Japan, and RR = 1.02, 5% CI: 0.65–1.59 in other countries).
There was no statistical heterogeneity in studies from Japan nomat-
ter whether prevalence, incidence, or sex-speciﬁc data were considered
(Table 2). Similarly, clinical heterogeneity was also small because most
studies from Japan used a similar methodology (Table 1). Incidence-
only data from Japan (adjusted at least for age, BMI, and smoking),
showed the same relationships as the main analysis. Studies from
Japan were mostly well adjusted including multiple components of
the MetS. The RR for men versus women in Japan was 0.99 (95% CI:
0.83–1.18, P = 0.89). Heterogeneity was large across other countries
and most data were not sex-speciﬁc. There was no statistical evidence
for publication bias (P = 0.72 in Japan, P = 0.49 in other countries),
and sequential exclusion of each estimate one at a time showed similar-
ly little impact on the pooled estimates (Figs. S1–S4).
Among cross-sectional studies included in our analyses, the unad-
justed pooled prevalence of hepatic steatosis was 31% (95% CI: 23–
39%) among non-drinkers in Japan and 26% (95% CI: 20–33%) among
drinkers b20 g/day. In countries other than Japan, the prevalence was
28% (95% CI: 23–32%) among non-drinkers and 28% (95% CI: 21–36%)
among drinkers b20 g/day average alcohol consumption. The preva-
lence of hepatic steatosis in women was about half compared to men
in Japan (17% [95% CI: 6–33%], and 33% [95% CI: 28–38%], respectively),
few studies provided sex-speciﬁc data in other countries. In meta-Table 2
Pooled relative risks for the relationship between alcohol consumption (b20 g/day) and hepat
All countries Japan
Population Estimates, casesb (No.) RR (95% CI) I2 (%) Estimates, casesb (No.)
All studies 22 (18,682) 0.85 (0.75–0.96) 86 14 (13,335)
Men 7 (7546) 0.80 (0.68–0.95) 82 6 (6949)
Women 7 (4554) 0.74 (0.66–0.83) 0 5 (3714)
Cohort studies 7 (3146) 0.78 (0.73–0.84) 6 (2333)
Men NA NA NA 2 (634)
Women NA NA NA 2 (178)
NA, not applicable.
a For difference Japan vs other countries.
b Cases of hepatic steatosis.regression models, overall prevalence rates of hepatic steatosis did not
explain any heterogeneity among all countries (adjusted RR = 1.00,
95% CI: 0.99–1.01, P = 0.79) or among Japanese studies (adjusted
RR = 1.00, 95% CI: 0.99–1.00, P = 0.24); however, in other countries
there was a borderline signiﬁcant relationship with a 3% increase in
RR per 1% increase in baseline prevalence of hepatic steatosis (adjusted
RR=1.03, 95% CI: 0.997–1.058, P= 0.064).Mean age did not show any
effects on the pooled RRs when all studies (adjusted RR= 1.00, 95% CI:
0.96–1.04, P = 0.85), Japanese studies (adjusted RR = 1.01, 95% CI:
0.97–1.06, P = 0.49), or countries other than Japan (adjusted RR =
1.01, 95% CI: 0.94–1.08, P = 0.71) were considered.
Studies that adjusted formultiple components of theMetS including
BMI showed the same relationshipswith regard to alcohol consumption
and hepatic steatosis in Japan (adjusted RR = 0.77, 95% CI: 0.72–0.83,
P = b0.001) (Tsunoda et al., 2014; Moriya et al., 2013; Moriya et al.,
2011; Hamaguchi et al., 2005; Gunji et al., 2009; Hiramine et al., 2011;
Doi et al., 2010; Hamabe et al., 2011). Only two studies from China
(Xu et al., 2010; Liu et al., 2014) were available for such an analysis
from other countries (adjusted RR = 0.84, 95% CI: 0.71–0.996, P =
0.045).
A study from Germany (Lau et al., 2015) showed interaction effects
betweenBMI andboth average andbinge alcohol consumption. Howev-
er, participants with hepatic steatosis in this study were also 9 (men)
and 16 (women) years older than participants without hepatic
steatosis. A Finnish study (Suomela et al., 2015) showed detrimental as-
sociations for b20 g/day in both obese and non-obese participants. A
Japanese study (Tsunoda et al., 2014) showed that physical activity
may have differential effects on the development of hepatic steatosis
in heavy and non-heavy drinkers.
Binge drinking (deﬁned as ≥5 standard drinks per day on at least one
occasion in the last 30 days) in comparison to other drinkers (adjusted
for age, BMI, HbA1c, average daily alcohol consumption, andmenopaus-
al status inwomen)was detrimentally associatedwith hepatic steatosis
in men but not in women in one study from Germany (Lau et al., 2015).
Two other studies from Japan (Moriya et al., 2015; Hiramine et al., 2011)
showed a similar detrimental relationship inmen, but the datawere not
adjusted for any potential confounders.
3.2. Dose Response Meta-analyses
Adjusted non-linear dose-response RR relationships (data available
up to 80 g/day) in comparison to non-drinkers in Japan (Moriya et al.,
2015; Moriya et al., 2013; Moriya et al., 2011; Hamaguchi et al., 2012;
Hashimoto et al., 2015; Hiramine et al., 2011) are shown in Figs. 3
(men) and 4 (women). There was strong statistical evidence for a
non-linear relationship for bothmen andwomen, and in cohort studies
(Table 3). The dose-response risk relationship in men was non-linear
and inverse with no evidence for a detrimental effect (Fig. 3). The risk
curve in women was J-shaped and turned to a detrimental association
with increasing alcohol consumption; a statistical signiﬁcant beneﬁcial
effect was seen below 20 g/day (Fig. 4). Aside from Japanese studies,ic steatosis compared to non-drinkers.
Other countries
RR (95% CI) I2 (%) Estimates, casesb (No.) RR (95% CI) I2 (%) Pa
0.75 (0.71–0.79) 0 8 (5346) 1.05 (0.86–1.30) 84 0.001
0.73 (0.68–0.78) 0 1 (597) 1.68 (1.26–2.23) NA 0.002
0.72 (0.62–0.83) 0 2 (840) 0.80 (0.61–1.04) 28 0.49
0.78 (0.72–0.84) 1 (813) 0.81 (0.66–0.99)
0.77 (0.70–0.84) 0 NA NA NA NA
0.72 (0.58–0.89) 0 NA NA NA NA
NOTE: Weights are from random effects analysis
Overall  (I-squared = 84.8%, p = 0.000)
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Fig. 2. Hepatic steatosis in alcohol drinkers b20 g/day in comparison to non-drinkers (relative risk on the log scale).
326 M. Roerecke et al. / EBioMedicine 8 (2016) 317–330only one German study (Lau et al., 2015) had dose-response data be-
yond 20 g/day. The reported relationships were increasingwith no ben-
eﬁcial effects in men (data available for up to 80 g/day), and non-linear
and inverse in women (data available for up to 40 g/day) (Lau et al.,
2015).
4. Discussion
Using high-quality epidemiological evidence, the association be-
tween alcohol consumption as a risk factor for hepatic steatosis was0.50
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Fig. 3.Dose-response relationships between alcohol consumption and hepatic steatosis in
Japan, men (n = 6 estimates, relative risk on the log scale).complex and non-linear, showing marked differences by ethnicity. At
moderate alcohol intake (up to 20 g/day), studies from Japan showed
a beneﬁcial association,whereas studies from other countries, including
China, Europe and North America, showed no overall association. The
difference between studies from Japan and other countries was consis-
tent and independent of the adjustment for confounding for metabolic
risk factors, baseline prevalence of hepatic steatosis, and mean age at
baseline. This questions the usefulness of terms such as ‘alcoholic’ or
‘non-alcoholic’, at least for hepatic steatosis, and highlights the need0.50
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Fig. 4.Dose-response relationships between alcohol consumption and hepatic steatosis in
Japan, women (n = 5 estimates, relative risk on the log scale).
Table 3
Spline regression coefﬁcients for the non-linear relationship between alcohol consumption and hepatic steatosis compared to non-drinkers in Japan.
Sex Estimates No. Casesa No. Coefﬁcient 1 Coefﬁcient 2
beta SE P I2(%) beta SE P I2(%)
All studies
Both sexes 11 15,728 −0.0224 0.0021 b0.001 6 0.0371 0.0049 b0.001 16
Men 6 11,692 −0.0242 0.0024 b0.001 0 0.0338 0.0045 b0.001 0
Women 5 4036 −0.0234 0.0091 0.010 47 0.0539 0.0193 0.005 40
Cohort studies
Both sexes 4 2310 −0.0230 0.0035 b0.001 0 0.0217 0.0043 b0.001 0
SE, standard error
a Cases of hepatic steatosis.
327M. Roerecke et al. / EBioMedicine 8 (2016) 317–330and importance of evidence frommultiple populations of diverse drink-
ing patterns and ethnic backgrounds. Others have noted that thresholds
for non-alcoholic and alcoholic steatosis are arbitrary and a distinction
between the two seems impossible (Nascimbeni et al., 2013; Volzke,
2012). Our results support this view. Nevertheless, there was a lack of
data for high alcohol intake in countries other than Japan to draw ﬁrm
conclusions about a dose-response relationship beyond moderate alco-
hol intake.
Sex was an important effect modiﬁer when thewhole range of alco-
hol consumption was considered. In general, consequences of heavy al-
cohol use appear to bemore negative for women than formen based on
higher blood alcohol levels because of smaller body size, lower body
water content, and lower gastric alcohol dehydrogenase activity
(Lieber, 2004; Zimmerman, 1999).
Across countries, binge drinking inmoderate drinkers in comparison
to non-binge drinkers was consistently associated with higher risk for
hepatic steatosis in men, though evidence was scarce and mostly unad-
justed. A potential explanation of the detrimental association in men
may be that in high doses, as the doses ingested in binge-drinking,
there is a dose dependent alcohol-induced hepatotoxicity (Lieber,
2004; Zimmerman, 1999; Zimmerman and KG, 1955). The one study
reporting results for women did not show evidence for an association;
however, binge drinking is usually less prevalent amongwomen.Higher
prevalence and volume of binge drinking in men might explain the sex
discrepancy; however, few data were available for such analyses and
conclusions need to be treated with caution.
4.1. Limitations
It should be noted that some subgroup analyses investigating poten-
tial effect modiﬁcation by study characteristics were subject to low
power because of the small number of studies in several subgroups. Fur-
thermore, we cannot derive any conclusions on the shape of the risk
curve N80 g/day because of the lack of data. People with very heavy al-
cohol intake, such as people with alcohol use disorders, are usually
missed in studies included in our review, and rates of liver diseases
are certainly much higher (Roerecke and Rehm, 2014a). Although self-
reported alcohol consumption seems to be reasonably valid
(Greenﬁeld, 2000), some drinkers and non-drinkers may change their
alcohol consumption over time (Kerr et al., 2002; Rehm et al., 2008),
leading to over- or under-estimation of alcohol intake. Thus, all drinking
groups we have identiﬁed may have been subject to misclassiﬁcation
bias, as they were in the primary studies.
Most studies from Japan were from popular free health screenings
associated with the workplace and may constitute a different popula-
tion compared to studies from other countries. However, baseline prev-
alence rates in Japanese studies were very similar to what is known
about the prevalence of hepatic steatosis in the general population. In
fact, the relation between alcohol consumption and hepatic steatosis
in Japan was so consistent that there was no heterogeneity to be ex-
plained. Nevertheless, we cannot draw conclusions for countries other
those included in our analysis. Furthermore, because all data werefrom high-income countries, malnutrition seems unlikely to explain
our ﬁndings.
Most of the data outside of Japanwas based on cross-sectional stud-
ies making it impossible to determine a temporal exposure-disease re-
lationship. However, ﬁve studies from Japan provided well-adjusted
incidence data with no difference in comparison to prevalence data,
similar to comparisons by sex and adjustment, all showing a substantial
beneﬁcial effect of alcohol consumption on hepatic steatosis. Despite
the variation in baseline prevalence rates of hepatic steatosis by sex,
there was no heterogeneity by sex among studies from Japan in terms
of risk relationships between alcohol and hepatic steatosis. Data from
other countries were more heterogeneous, showing no overall associa-
tion, but a potential beneﬁcial association in women. There were not
enough data to systematically investigate observed heterogeneity in
studies from other countries, though the baseline prevalence of hepatic
steatosis may play a role. The larger heterogeneity in studies from other
countries compared to studies from Japan may be explained by the fact
that in an ethnically homogeneous population lives in Japan, while the
rest of the studies comprise of ethnically more heterogeneous popula-
tions, including drinking cultures and diets. Because of the lack of inci-
dence data and adjustment for other risk factors for hepatic steatosis
in countries other than Japan, we rate the quality of the evidence as
rather poor outside of Japan.
Potential explanations for the observed differences in risk for hepatic
steatosis from alcohol consumption in Japan compared to other coun-
tries are speculative at this point. Although excessive alcohol consump-
tion leads to morphological changes, which can occur despite an
adequate nutritional state (Zimmerman and KG, 1955; Neuman et al.,
2014b), the relationship with moderate alcohol consumption may be
different. Differences in nutrition and microbiota can affect immune
cells in the liver, which in turn release various inﬂammatory cytokines
and recruit neutrophils, leading to the activation of macrophages
(Kupffer cells) and to the inﬂammatory cascade (Neuman et al.,
2014b). This phenomenon may be an additional explanation of the re-
sults seen in this meta-analysis (Grove et al., 1997; Neuman, 2003).
The liver is involved in critical steps of lipid metabolism, including de
novo synthesis and uptake of free fatty acids from diet as well as from
lipolysis of the adipose tissue. Additionally, utilization of the free fatty
acids, synthesis of triglycerides and their release fromhepatocytes is de-
pendent on several steps that can differ in genetically different popula-
tion (Neuman et al., 2014b). We were unable to investigate genetic
characteristics of the individual participants or the use of speciﬁc diets
in our analysis because of the lack of data.
Although smoking status was adjusted for in most of the studies
from Japan, including cohort studies, the effect of tobacco use on hepatic
steatosis may be larger than is captured by a dichotomous variable such
as status of smoking. Tobacco smoke creates a state of chronic inﬂam-
mation leading to pro-inﬂammatory cytokine activation, impaired anti-
oxidantmetabolism and change in lipid proﬁle of the individuals aswell
as potentiating insulin resistance syndrome and diabetes, all of which
are risk factors for NAFLD (Attvall et al., 1993; Will et al., 2001; Zein,
2010).
328 M. Roerecke et al. / EBioMedicine 8 (2016) 317–330Studies from Japan and other countries have shown a strong associ-
ation of BMI with NAFLD (Li et al., 2016a; Matsuura et al., 2013) and
other more severe forms of liver disease in studies of people with alco-
hol use disorders with much more alcohol intake than we observed in
our analysis (Naveau et al., 2013; Naveau et al., 2009; Raynard et al.,
2002). Almost all studies in our analysis were adjusted for BMI, visceral
fat, or waist circumference, and these potential confounders did not ex-
plain the differential relationships between Japan and other countries.
However, an interaction effect between BMI and alcohol intake was
shown in two European studies (Lau et al., 2015; Bellentani et al.,
2000). One Japanese study showed that alcohol intake was beneﬁcial
in both obese (BMI ≥ 25) and non-obese (BMI b 25) participants using
unadjusted data (Nishioji et al., 2015). More research taking into ac-
count a possible interaction effect of BMI, other metabolic risk factors,
and alcohol intake is needed to further elucidate the complex interplay
of risk factors in the development of hepatic steatosis.
4.2. Implications
Having examined one of the most prevalent risk factors for non-
communicable diseases in relation to the most prevalent liver disease
globally, we found a complicated and non-linear relationship between
the twowith unclear but plausible pathways. There are plausible expla-
nations for a non-linear association (i.e. a beneﬁcial and detrimental ef-
fect depending on the dose and pattern of intake) of alcohol
consumption on hepatic steatosis based on short-term biochemical ev-
idence. Systematic evidence from trials for biomarkers related to fat and
insulin metabolism showed a positive relationship with alcohol in rela-
tion to high density lipoproteins, an inverse relationship with low den-
sity lipoproteins, and no association with triglycerides (Brien et al.,
2011). A reduction in HbA1c and fasting insulin with alcohol consump-
tion, but not for insulin sensitivity or fasting glucosewas reported in an-
other meta-analysis of trial data (Schrieks et al., 2015). We found some
evidence for effectmodiﬁcation frombinge drinking evenwhen average
alcohol intake is moderate inmen in our analysis. Similarly complicated
and non-linear associationswere reported using observational evidence
on alcohol and ischemic heart disease (Roerecke and Rehm, 2014b), di-
abetes (Knott et al., 2015; Li et al., 2016b), and MetS (Loria et al., 2014;
Sun et al., 2014). Although we analyzed observational studies, we rate
the evidence for a beneﬁcial effect of low alcohol consumption in
Japan as relatively high because of its quality, magnitude, consistency,
and precision. Evidence for an association of alcohol on hepatic steatosis
from other countries in our analysis was mixed with large heterogene-
ity. More research on the role of alcohol consumption patterns and
other risk factors in the development of hepatic steatosis and sex differ-
ences in countries other than Japan is needed as there were too few
studies to derive meaningful conclusions. Though confounding did not
seem to explain the ﬁndings of differential relations between Japan
and other countries, interaction effects may play an important role. In-
teraction effects among risk factors such as alcohol consumption, BMI,
diet, physical activity, and smoking should be routinely considered in
sample size calculations for future studies and analyses using non-
linear models for current studies in order to make progress in the un-
derstanding of combined and individual contributions of each risk
factor.
5. Conclusions
The etiology of liver diseases is multi-factorial and given the results
of this meta-analysis, alcohol's effects on liver steatosis are complex
and non-linear. There was good evidence that alcohol consumption
b20 g/day has a beneﬁcial effect on the development of hepatic steatosis
in Japan, in contrast to other high-income countries. At least sex, ethnic-
ity, BMI, and possibly drinking patterns seem tomodify the relationship
between alcohol consumption and hepatic steatosis. Large heterogene-
ity outside Japan precludes us frommaking ﬁrm judgements. More andhigher quality research in diverse ethnic populations is needed to fur-
ther clarify this relationship.
Acknowledgements
Conﬂict of Interest
MRand JR report grants fromNational Institutes of Health (NIH), Na-
tional Institute on Alcohol Abuse and Alcoholism (NIAAA), during the
conduct of the study. MN and RN report no conﬂicts of interest.
Financial Support
The work was ﬁnancially supported by a grant from the National In-
stitute on Alcohol Abuse and Alcoholism (NIAAA) at the National Insti-
tutes of Health (grant number R21AA023521-01A1 toMR). The sponsor
of the study (NIAAA) had no role in study design, data collection, data
analysis, data interpretation, or writing of the report. The authors col-
lected the data, and had full access to all of the data in the study. The au-
thors also had ﬁnal responsibility for the decision to submit the study
results for publication.
Author's Contributions
MR designed the study, and oversaw and conducted the literature
review, data extraction, statistical analysis, data interpretation, article
preparation, article review, and correspondence. JR contributed to de-
sign and data interpretation, article preparation, and article review. RN
contributed to the literature review, article preparation, and article re-
view. MN contributed to the design, literature review, data interpreta-
tion, article preparation, and article review. All authors contributed to
the ﬁnal article and approved the ﬁnal version.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.023.
References
Attvall, S., Fowelin, J., Lager, I., Von Schenck, H., Smith, U., 1993. Smoking induces insulin
resistance–a potential link with the insulin resistance syndrome. J. Intern. Med. 233
(4), 327–332.
Ballestri, S., Zona, S., Targher, G., et al., 2015. Nonalcoholic Fatty Liver Disease Is Associated
with an almost two-Fold Increased Risk of Incident Type 2 Diabetes and Metabolic
Syndrome. Evidence from a systematic review and meta-analysis, Journal of Gastro-
enterology and Hepatology http://dx.doi.org/10.1111/jgh.13264 (Epub ahead of
print).
Bellentani, S., Saccoccio, G., Costa, G., et al., 1997. Drinking habits as cofactors of risk for
alcohol induced liver damage. Dionysos Study Group. Gut 41 (6), 845–850.
Bellentani, S., Saccoccio, G., Masutti, F., et al., 2000. Prevalence of and risk factors for he-
patic steatosis in Northern Italy. Ann. Intern. Med. 132 (2), 112–117.
Bonci, E., Chiesa, C., Versacci, P., Anania, C., Silvestri, L., Paciﬁco, L., 2015. Association of
nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic
review and meta-analysis. BioMed Res. Int. 2015, 213737.
Brien, S.E., Ronksley, P.E., Turner, B.J., Mukamal, K.J., Ghali, W.A., 2011. Effect of alcohol
consumption on biological markers associated with risk of coronary heart disease:
systematic review and meta-analysis of interventional studies. BMJ 342, d636.
Byass, P., 2014. The global burden of liver disease: a challenge for methods and for public
health. BMC Med. 12, 159.
Byrne, C.D., Targher, G., 2015. NAFLD: a multisystem disease. J. Hepatol. 62 (1 Suppl),
S47–S64.
Caballeria, L., Pera, G., Auladell, M.A., et al., 2010. Prevalence and factors associated with
the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur.
J. Gastroenterol. Hepatol. 22 (1), 24–32.
Chalasani, N., Younossi, Z., Lavine, J.E., et al., 2012. The diagnosis andmanagement of non-
alcoholic fatty liver disease: practice guideline by the American Association for the
Study of Liver Diseases, American College of Gastroenterology, and the American Gas-
troenterological Association. Hepatology 55 (6), 2005–2023.
Chalmers, T.C., Smith Jr., H., Blackburn, B., et al., 1981. A method for assessing the quality
of a randomized control trial. Control. Clin. Trials 2 (1), 31–49.
DerSimonian, R., Laird, N., 1986. Meta-analysis in clinical trials. Control. Clin. Trials 7 (3),
177–188.
Detsky, A.S., Naylor, C.D., O'Rourke, K., McGeer, A.J., L'Abbe, K.A., 1992. Incorporating var-
iations in the quality of individual randomized trials into meta-analysis. J. Clin.
Epidemiol. 45 (3), 255–265.
Doi, T., Tanaka, S., Sato, Y., et al., 2010. Effect of alcohol consumption on the prevalence of
fatty liver disease. Acta Hepato. Jpn. 51 (9), 501–507.
EASL, 2012. Clinical practical guidelines: management of alcoholic liver disease. J. Hepatol.
57 (2), 399–420.
329M. Roerecke et al. / EBioMedicine 8 (2016) 317–330Egger, M., Smith, G.D., Schneider, M., Minder, C., 1997. Bias inmeta-analysis detected by a
simple, graphical test. BMJ 315 (7109), 629–634.
Freeman, M.F., Tukey, J.W., 1950. Transformations related to the angular and the square
root. Ann. Math. Stat. 21 (4), 607–611.
Greenﬁeld, T.K., 2000. Ways of measuring drinking patterns and the difference they
make: experience with graduated frequencies. J. Subst. Abus. 12 (1–2), 33–49.
Greenland, S., O'Rourke, K., 2001. On the bias produced by quality scores in meta-
analysis, and a hierarchical view of proposed solutions. Biostatistics 2 (4),
463–471.
Grove, J., Daly, A.K., Bassendine, M.F., Day, C.P., 1997. Association of a tumor necrosis fac-
tor promoter polymorphism with susceptibility to alcoholic steatohepatitis.
Hepatology 26 (1), 143–146.
Gunji, T., Matsuhashi, N., Sato, H., et al., 2009. Light and moderate alcohol consumption
signiﬁcantly reduces the prevalence of fatty liver in the Japanese male population.
Am. J. Gastroenterol. 104 (9), 2189–2195.
Hamabe, A., Uto, H., Imamura, Y., et al., 2011. Impact of cigarette smoking on onset of
nonalcoholic fatty liver disease over a 10-year period. J. Gastroenterol. 46 (6),
769–778.
Hamaguchi, M., Kojima, T., Takeda, N., et al., 2005. The metabolic syndrome as a predictor
of nonalcoholic fatty liver disease. Ann. Intern. Med. 143 (10), 722–728.
Hamaguchi, M., Kojima, T., Ohbora, A., Takeda, N., Fukui, M., Kato, T., 2012. Protective ef-
fect of alcohol consumption for fatty liver but not metabolic syndrome. World
J. Gastroenterol. 18 (2), 156–167.
Hamling, J., Lee, P., Weitkunat, R., Ambuhl, M., 2008. Facilitating meta-analyses by deriv-
ing relative effect and precision estimates for alternative comparisons from a set of
estimates presented by exposure level or disease category. Stat. Med. 27 (7),
954–970.
Hashimoto, Y., Hamaguchi, M., Kojima, T., et al., 2015. Modest alcohol consumption re-
duces the incidence of fatty liver in men: a population-based large-scale cohort
study. J. Gastroenterol. Hepatol. 30 (3), 546–552.
Herbison, P., Hay-Smith, J., Gillespie, W.J., 2006. Adjustment of meta-analyses on
the basis of quality scores should be abandoned. J. Clin. Epidemiol. 59 (12),
1249–1256.
Hernaez, R., Lazo, M., Bonekamp, S., et al., 2011. Diagnostic accuracy and reliability of ul-
trasonography for the detection of fatty liver: a meta-analysis. Hepatology 54 (3),
1082–1090.
Higgins, J., Thompson, S.G., 2002. Quantifying heterogeneity in a meta-analysis. Stat. Med.
21 (11), 1539–1558.
Hiramine, Y., Imamura, Y., Uto, H., et al., 2011. Alcohol drinking patterns and the risk of
fatty liver in Japanese men. J. Gastroenterol. 46 (4), 519–528.
Kerr, W.C., Fillmore, K.M., Bostrom, A., 2002. Stability of alcohol consumption over time:
evidence from three longitudinal surveys from the United States. J. Stud. Alcohol 63
(3), 325–333.
Knott, C., Bell, S., Britton, A., 2015. Alcohol consumption and the risk of type 2 diabetes: a
systematic review and dose-response Meta-analysis of N1.9 million individuals from
38 observational studies. Diabetes Care 38 (9), 1804–1812.
LaBrecque, D.R., Abbas, Z., Anania, F., et al., 2014. World gastroenterology organisation
global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
J. Clin. Gastroenterol. 48 (6), 467–473.
Lau, K., Baumeister, S.E., Lieb, W., et al., 2015. The combined effects of alcohol consump-
tion and body mass index on hepatic steatosis in a general population sample of
European men and women. Aliment. Pharmacol. Ther. 41 (5), 467–476.
Lazo, Elizondo M., 2010. Epidemiology of Nonalcoholic Fatty Liver Disease in the
United States: Prevalence, Correlates and Mortality. John Hopkins University,
Baltimore, MD.
Li, L., Liu, D.W., Yan, H.Y., Wang, Z.Y., Zhao, S.H., Wang, B., 2016a. Obesity is an indepen-
dent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis
of 21 cohort studies. Obes. Rev.: Off J. Int. Assoc Study Obes.
Li, X.H., Yu, F.F., Zhou, Y.H., He, J., 2016b. Association between alcohol consumption and
the risk of incident type 2 diabetes: a systematic review and dose-response meta-
analysis. Am. J. Clin. Nutr.
Lieber, C.S., 2004. CYP2E1: from ASH to NASH. Hepatol. Res. 28 (1), 1–11.
Liu, P.J., Ma, F., Lou, H.P., Zhu, Y.N., Chen, Y., 2014. Relationship between serum uric acid
levels and hepatic steatosis in non-obese postmenopausal women. Climacteric 17
(6), 692–699.
Loria, P., Marchesini, G., Nascimbeni, F., et al., 2014. Cardiovascular risk, lipidemic pheno-
type and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease
due to varying etiology. Atherosclerosis 232 (1), 99–109.
Lozano, R., Naghavi, M., Foreman, K., et al., 2012. Global and regional mortality from 235
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the
global burden of disease study 2010. Lancet 380 (9859), 2095–2128.
Lu, H., Liu, H., Hu, F., Zou, L., Luo, S., Sun, L., 2013. Independent association between non-
alcoholic fatty liver disease and cardiovascular disease: a systematic review and
meta-analysis. Int. J. Endocrinol. 2013, 124958.
Mathurin, P., Deltenre, P., 2009. Effect of binge drinking on the liver: an alarming public
health issue? Gut 58 (5), 613–617.
Matsuura, B., Nunoi, H., Miyake, T., Hiasa, Y., Onji, M., 2013. Obesity and gastrointestinal
liver disorders in Japan. J. Gastroenterol. Hepatol. 28 (Suppl. 4), 48–53.
Miele, L., Dall'armi, V., Cefalo, C., et al., 2014. A case-control study on the effect of metabol-
ic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic
fatty liver disease. Genes Nutr. 9 (2), 383.
Vital signs: Binge drinking prevalence, frequency, and intensity among adults — United
StatesMMWR Morb. Mortal. Wkly Rep. 2012 61 (1), 14–19.
Moher, D., Pham, B., Jones, A., et al., 1998. Does quality of reports of randomised trials af-
fect estimates of intervention efﬁcacy reported in meta-analyses? Lancet 352 (9128),
609–613.Moriya, A., Iwasaki, Y., Ohguchi, S., et al., 2011. Alcohol consumption appears to pro-
tect against non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 33 (3),
378–388.
Moriya, A., Iwasaki, Y., Ohguchi, S., et al., 2013. Roles of alcohol drinking pattern in fatty
liver in Japanese women. Hepatol. Int. 7 (3), 859–868.
Moriya, A., Iwasaki, Y., Ohguchi, S., et al., 2015. Roles of alcohol consumption in fatty liver:
a longitudinal study. J. Hepatol. 62 (4), 921–927.
Naimi, T.S., Brewer, R.D., Mokdad, A., Denny, C., Serdula, M.K., Marks, J.S., 2003. Binge
drinking among US adults. JAMA 289 (1), 70–75.
Nascimbeni, F., Pais, R., Bellentani, S., et al., 2013. From NAFLD in clinical practice to an-
swers from guidelines. J. Hepatol. 59 (4), 859–871.
Naveau, S., Thaury, J., Barri-Ova, N., et al., 2009. Predictive factors for pure steatosis in al-
coholic patients. Alcohol. Clin. Exp. Res. 33 (6), 1104–1110.
Naveau, S., Dobrin, A.S., Balian, A., et al., 2013. Body fat distribution and risk factors
for ﬁbrosis in patients with alcoholic liver disease. Alcohol. Clin. Exp. Res. 37
(2), 332–338.
Neuman, M.G., 2003. Cytokines–central factors in alcoholic liver disease. Alcohol Res.
Health 27 (4), 307–316.
Neuman, M.G., Cohen, L.B., Nanau, R.M., 2014a. Biomarkers in nonalcoholic fatty liver dis-
ease. Can. J. Gastroenterol. Hepatol. 28 (11), 607–618.
Neuman, M.G., French, S.W., French, B.A., et al., 2014b. Alcoholic and non-alcoholic
steatohepatitis. Exp. Mol. Pathol. 97 (3), 492–510.
Newcombe, R.G., 1998. Two-sided conﬁdence intervals for the single proportion: compar-
ison of seven methods. Stat. Med. 17 (8), 857–872.
Nishioji, K., Sumida, Y., Kamaguchi, M., et al., 2015. Prevalence of and risk factors for non-
alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012.
J. Gastroenterol. 50 (1), 95–108.
Orsini, N., Bellocco, R., Greenland, S., 2006. Generalized least squares for trend estimation
of summarized dose-response data. Stata J. 6 (1), 40–57.
Orsini, N., Li, R., Wolk, A., Khudyakov, P., Spiegelman, D., 2012. Meta-analysis for linear
and nonlinear dose-response relations: examples, an evaluation of approximations,
and software. Am. J. Epidemiol. 175 (1), 66–73.
Peng, X.E., Lai, Z.S., Lu, Q.Q., Lin, J.Y., Lin, X., 2009. A hospital-based case-control study on
inﬂuencing factors of nonalcoholic fatty liver disease. Chin. J. Hepatol. 17 (7),
535–539.
Poli, A., Marangoni, F., Avogaro, A., et al., 2013. Moderate alcohol use and health: a con-
sensus document. Nutr. Metab. Cardiovasc. Dis. 23 (6), 487–504.
Raynard, B., Balian, A., Fallik, D., et al., 2002. Risk Factors of Fibrosis in Alcohol-Induces
Liver Diseases. Hepatology 35 (3), 635–638 Baltimore, Md.
Rehm, J., Roerecke, M., 2015. Patterns of drinking and liver cirrhosis — what do we know
and where do we go? J. Hepatol. 62 (5), 1000–1001.
Rehm, J., Irving, H., Ye, Y., Kerr, W.C., Bond, J., Greenﬁeld, T.K., 2008. Are lifetime abstainers
the best control group in alcohol epidemiology? On the stability and validity of re-
ported lifetime abstention. Am. J. Epidemiol. 168 (8), 866–871.
Roerecke, M., Rehm, J., 2014a. Cause-speciﬁc mortality risk in alcohol use disorder treat-
ment patients: a systematic review and meta-analysis. Int. J. Epidemiol. 43 (3),
906–919.
Roerecke, M., Rehm, J., 2014b. Alcohol consumption, drinking patterns, and ischemic
heart disease: a narrative review of meta-analyses and a systematic review and
meta-analysis of the impact of heavy drinking occasions on risk for moderate
drinkers. BMC Med. 12, 182.
Sattar, N., Forrest, E., Preiss, D., 2014. Non-alcoholic fatty liver disease. BMJ 349, g4596.
Schrieks, I.C., Heil, A.L., Hendriks, H.F., Mukamal, K.J., Beulens, J.W., 2015. The effect of al-
cohol consumption on insulin sensitivity and glycemic status: a systematic review
and meta-analysis of intervention studies. Diabetes Care 38 (4), 723–732.
Shield, K.D., Rylett, M., Gmel, G., Gmel, G., Kehoe-Chan, T.A., Rehm, J., 2013. Global alcohol
exposure estimates by country, territory and region for 2005–a contribution to the
comparative risk assessment for the 2010 global burden of disease study. Addiction
108 (5), 912–922.
Stroup, D.F., Berlin, J.A., Morton, S.C., et al., 2000. Meta-analysis of observational studies in
epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Ep-
idemiology (MOOSE) group. JAMA 283 (15), 2008–2012.
Sun, K., Ren, M., Liu, D., Wang, C., Yang, C., Yan, L., 2014. Alcohol consumption and risk of
metabolic syndrome: a meta-analysis of prospective studies. Clin. Nutr. 33 (4),
596–602.
Suomela, E., Oikonen, M., Virtanen, J., et al., 2015. Prevalence and determinants of fatty
liver in normal-weight and overweight young adults. The cardiovascular risk in
young Finns study. Ann. Med. 47 (1), 40–46.
Targher, G., Day, C.P., Bonora, E., 2010. Risk of cardiovascular disease in patients with non-
alcoholic fatty liver disease. N. Engl. J. Med. 363 (14), 1341–1350.
Thompson, S.G., Higgins, J.P., 2002. How should meta-regression analyses be undertaken
and interpreted? Stat. Med. 21 (11), 1559–1573.
Tsunoda, K., Kai, Y., Uchida, K., Kuchiki, T., Nagamatsu, T., 2014. Physical activity and risk
of fatty liver in people with different levels of alcohol consumption: a prospective co-
hort study. BMJ Open 4 (8), e005824.
Vernon, G., Baranova, A., Younossi, Z.M., 2011. Systematic review: the epidemiology and
natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
in adults. Aliment. Pharmacol. Ther. 34 (3), 274–285.
Volzke, H., 2012. Multicausality in fatty liver disease: is there a rationale to distinguish be-
tween alcoholic and non-alcoholic origin? World J. Gastroenterol. 18 (27),
3492–3501.
WHO, 2000. International Guide for Monitoring Alcohol Consumption and Related Harm
Geneva, Switzerland .
Will, J.C., Galuska, D.A., Ford, E.S., Mokdad, A., Calle, E.E., 2001. Cigarette smoking and di-
abetes mellitus: evidence of a positive association from a large prospective cohort
study. Int. J. Epidemiol. 30 (3), 540–546.
330 M. Roerecke et al. / EBioMedicine 8 (2016) 317–330Wong, V.W., Chu, W.C., Wong, G.L., et al., 2012. Prevalence of non-alcoholic fatty liver
disease and advanced ﬁbrosis in Hong Kong Chinese: a population study using
proton-magnetic resonance spectroscopy and transient elastography. Gut 61
(3), 409–415.
Xu, C., Yu, C., Xu, L., Miao, M., Li, Y., 2010. High serum uric acid increases the risk for non-
alcoholic fatty liver disease: a prospective observational study. PLoS One 5 (7),
e11578.
Yki-Jarvinen, H., 2014. Non-alcoholic fatty liver disease as a cause and a consequence of
metabolic syndrome. Lancet Diab. Endocrinol. 2 (11), 901–910.
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., 2015. Global ep-
idemiology of non-alcoholic fatty liver disease-Meta-analytic assessment ofprevalence. Incidence Outcomes. Hepatology http://dx.doi.org/10.1002/hep.28431
(Epub ahead of print).
Zein, C.O., 2010. Clearing the smoke in chronic liver diseases. Hepatology 51 (5),
1487–1490.
Zimmerman, H., 1999. Adverse Effects of Drugs and Other Chemicals on the Liver. second
ed. Lippincott-Williams-Wilkins, Philadelphia.
Zimmerman, H.J., Ishak, K.G., 1955. Non-alcoholic steatohepatitis and other forms of
pseudoalcoholic liver disease. In: Hall, P. (Ed.), Alcoholic Liver Disease Pathology
and Pathogenesis, second ed. Edward Arnold, London, pp. 165–198.
